Akebia Therapeutics Inc. (AKBA) 9.32 $AKBA
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
Akebia to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 2:00 p.m. Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City.
AKBA: 9.32 (+0.51)
5 Stocks Ready for Breakouts: Akebia Therapeutics, Hutchinson and More
at The Street - Mon Jan 12, 9:59AM CST
Trading stocks that trigger major breakouts can lead to massive profits.
OPTT: 0.50 (-0.02), HTCH: 3.71 (+0.09), LNCO: 12.30 (+0.28), AKBA: 9.32 (+0.51), CSTM: 18.77 (+0.10)
Akebia Progresses with Chronic Kidney Disease Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 4:00PM CST
Akebia (AKBA) completed the enrolment of two of its planned cohorts of a phase II study on AKB-6548 ahead of its scheduled time.
INCY: 75.94 (+0.28), AKBA: 9.32 (+0.51), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Akebia completes enrollment in anemia trial
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 3:58PM CST
AKBA: 9.32 (+0.51)
Akebia Completes Enrollment in the Two Planned Cohorts of its Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Mon Jan 05, 3:01PM CST
-- Expanding Trial to Include Third Cohort, with Top-Line Data Still Expected in Third Quarter of 2015 --
AKBA: 9.32 (+0.51)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 6:50AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
AKBA: 9.32 (+0.51)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Thu Dec 04, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11,2014 at 1:00 p.m. Eastern Time. The conference will take place at Crowne Plaza Times Square Manhattan in New York City.
AKBA: 9.32 (+0.51)
Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan
Business Wire - Mon Nov 17, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), announced today that John P. Butler, President and Chief Executive Officer of Akebia, has established a personal stock purchasing plan to acquire shares of the company's common stock. The purchasing plan complies with Section 10b5-1 of the Securities Exchange Act of 1934, as amended, which enables securities holders to adopt pre-arranged stock purchasing plans for the acquisition of predetermined amounts of securities on a non-discretionary basis.
AKBA: 9.32 (+0.51)
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 9.32 (+0.51)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 9.63 (+0.15), JRJC: 5.46 (+0.16), NAVB: 1.60 (unch), SANW: 4.80 (+0.19), PLPM: 1.49 (-0.05), RYN: 28.02 (-1.15), INFU: 2.72 (+0.01), LIOX: 5.57 (+0.10), DY: 37.84 (+0.35), MTZ: 20.75 (+0.53), CGIX: 7.07 (unch), MUX: 1.10 (+0.06), OREX: 5.55 (+0.10), URRE: 1.75 (+0.01), ACHN: 10.89 (-0.20), REN: 1.14 (unch), MPO: 1.00 (-0.02), AKBA: 9.32 (+0.51), TRX: 0.57 (+0.01), PLNR: 6.63 (-0.07)
Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST
AKBA: 9.32 (+0.51)
Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 9.32 (+0.51)
Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 9.32 (+0.51)
Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT
AKBA: 9.32 (+0.51)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
Akebia to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 2:00 p.m. Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City.
AKBA: 9.32 (+0.51)
5 Stocks Ready for Breakouts: Akebia Therapeutics, Hutchinson and More
at The Street - Mon Jan 12, 9:59AM CST
Trading stocks that trigger major breakouts can lead to massive profits.
OPTT: 0.50 (-0.02), HTCH: 3.71 (+0.09), LNCO: 12.30 (+0.28), AKBA: 9.32 (+0.51), CSTM: 18.77 (+0.10)
Akebia Progresses with Chronic Kidney Disease Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 4:00PM CST
Akebia (AKBA) completed the enrolment of two of its planned cohorts of a phase II study on AKB-6548 ahead of its scheduled time.
INCY: 75.94 (+0.28), AKBA: 9.32 (+0.51), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Akebia completes enrollment in anemia trial
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 3:58PM CST
AKBA: 9.32 (+0.51)
Akebia Completes Enrollment in the Two Planned Cohorts of its Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Mon Jan 05, 3:01PM CST
-- Expanding Trial to Include Third Cohort, with Top-Line Data Still Expected in Third Quarter of 2015 --
AKBA: 9.32 (+0.51)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 6:50AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
AKBA: 9.32 (+0.51)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Thu Dec 04, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11,2014 at 1:00 p.m. Eastern Time. The conference will take place at Crowne Plaza Times Square Manhattan in New York City.
AKBA: 9.32 (+0.51)
Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan
Business Wire - Mon Nov 17, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), announced today that John P. Butler, President and Chief Executive Officer of Akebia, has established a personal stock purchasing plan to acquire shares of the company's common stock. The purchasing plan complies with Section 10b5-1 of the Securities Exchange Act of 1934, as amended, which enables securities holders to adopt pre-arranged stock purchasing plans for the acquisition of predetermined amounts of securities on a non-discretionary basis.
AKBA: 9.32 (+0.51)
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 9.32 (+0.51)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 9.63 (+0.15), JRJC: 5.46 (+0.16), NAVB: 1.60 (unch), SANW: 4.80 (+0.19), PLPM: 1.49 (-0.05), RYN: 28.02 (-1.15), INFU: 2.72 (+0.01), LIOX: 5.57 (+0.10), DY: 37.84 (+0.35), MTZ: 20.75 (+0.53), CGIX: 7.07 (unch), MUX: 1.10 (+0.06), OREX: 5.55 (+0.10), URRE: 1.75 (+0.01), ACHN: 10.89 (-0.20), REN: 1.14 (unch), MPO: 1.00 (-0.02), AKBA: 9.32 (+0.51), TRX: 0.57 (+0.01), PLNR: 6.63 (-0.07)
Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST
AKBA: 9.32 (+0.51)
Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 9.32 (+0.51)
Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 9.32 (+0.51)
Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT
AKBA: 9.32 (+0.51)
